Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 08 / 16 / 2018

Articles

Table of Content

Category: Vol 6 Issue 2
Hits: 29
scover V6I1  
 PDF Version  pdf32  [ PDF-15.60MB-128pages ]
 

Table of Contents

Original Article

Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review
Duminda Suraweera, Christina Fanous, Melissa Jimenez, Myron J. Tong, Sammy Saab
Abstract ] [ Html ] [ PDF Full-text ] 119-126 Doi: 10.14218/JCTH.2017.00064

Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury
Meir Mizrahi, Tomer Adar, Gadi Lalazar, Dean Nachman, Madi El Haj, Ami Ben Ya’acov, Yoav Lichtenstein, Yehudit Shabat, Dimitri Kanovich, Lida Zolotarov, Yaron Ilan
Abstract ] [ Html ] [ PDF Full-text ] 127-134 Doi: 10.14218/JCTH.2017.00071

Vitamin D Deficiency and Its Relationship with Child-Pugh Class in Patients with Chronic Liver Disease
Zubia Jamil, Sharmin Arif, Anum Khan, Asghar Aurangzeb Durrani, Nayyar Yaqoob
Abstract ] [ Html ] [ PDF Full-text ] 135-140 Doi: 10.14218/JCTH.2017.00055

Effect of Genistein in Comparison with Trichostatin A on Reactivation of DNMTs Genes in Hepatocellular Carcinoma
Masumeh Sanaei, Fraidoon Kavoosi, Abazar Roustazadeh, Fatemeh Golestan
Abstract ] [ Html ] [ PDF Full-text ] 141-146 Doi: 10.14218/JCTH.2018.00002

HCV Therapy Follow-up Fractionation (CTF2) by Intra-PBMC Nested RNA PCR Recognizes Early Virologic Response and Relapse
Mohamed Darwish Ahmed Abd Alla, Saleh Ahmed Elibiary, Ramy Hassan Elshaboury, George Y. Wu, Reham M. Dawood, Mostafa Kamel El Awady
Abstract ] [ Html ] [ PDF Full-text ] 147-154 Doi: 10.14218/JCTH.2017.00077

Review Article

Occult Hepatitis C Virus Infection: A Review
Alyssa Austria, George Y. Wu
Abstract ] [ Html ] [ PDF Full-text ] 155-160 Doi: 10.14218/JCTH.2017.00053

Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies
Wolfgang Poller, Arash Haghikia, Mario Kasner, Ziya Kaya, Udo Bavendiek, Heiner Wedemeier, Hans-J?rg Epple, Carsten Skurk, Ulf Landmesser
Abstract ] [ Html ] [ PDF Full-text ] 161-167 Doi: 10.14218/JCTH.2017.00057

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Heather S. Snyder, Sami A. Sakaan, Katherine L. March, Osama Siddique, Rosann Cholankeril, Carolyn D. Cummings, Chiran Gadiparthi, Sanjaya K. Satapathy, Aijaz Ahmed, George Cholankeril
Abstract ] [ Html ] [ PDF Full-text ] 168-174 Doi: 10.14218/JCTH.2017.00050

Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
Patrick Vande Lune, Ahmed K. Abdel Aal, Sergio Klimkowski, Jessica G. Zarzour, Andrew J. Gunn
Abstract ] [ Html ] [ PDF Full-text ] 175-188 Doi: 10.14218/JCTH.2017.00045

Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review
Shamar Young, Andrew J. Taylor, Tina Sanghvi
Abstract ] [ Html ] [ PDF Full-text ] 189-197 Doi: 10.14218/JCTH.2017.00059

Non-invasive in vivo Imaging Grading of Liver Fibrosis
Hanyu Jiang, Tianying Zheng, Ting Duan, Jie Chen, Bin Song
Abstract ] [ Html ] [ PDF Full-text ] 198-207 Doi: 10.14218/JCTH.2017.00038

Differentiating Cystic Liver Lesions: A Review of Imaging Modalities, Diagnosis and Management
Marianna G. Mavilia, Tina Pakala, Marco Molina, George Y. Wu
Abstract ] [ Html ] [ PDF Full-text ] 208-216 Doi: 10.14218/JCTH.2017.00069

Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease
Shujing Lv, Sushan Jiang, Shousheng Liu, Quanjiang Dong, Yongning Xin, Shiying Xuan
Abstract ] [ Html ] [ PDF Full-text ] 217-221 Doi: 10.14218/JCTH.2018.00021

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners
Francesca Patella, Filippo Pesapane, Enrico Maria Fumarola, Ilaria Emili, Riccardo Spairani, Salvatore Alessio Angileri, Silvia Tresoldi, Giuseppe Franceschelli, Gianpaolo Carrafiello
Abstract ] [ Html ] [ PDF Full-text ] 222-236 Doi: 10.14218/JCTH.2017.00062

Case Report

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series
Dominik Bettinger, Stefan Schlabe, Sven Pischke, Michael R. Mallmann, Mignon-Denise Keyver-Paik, Walther Kuhn, Christian P. Strassburg, Robert Thimme, Ulrich Spengler
Abstract ] [ Html ] [ PDF Full-text ] 237-240 Doi: 10.14218/JCTH.2017.00063

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series

Category: Vol 6 Issue 2
Hits: 35

Case Report

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series

Dominik Bettinger#,*,1,2, Stefan Schlabe#,3,4, Sven Pischke5, Michael R. Mallmann7, Mignon-Denise Keyver-Paik4,6, Walther Kuhn4,6, Christian P. Strassburg3,4, Robert Thimme‡,1 and Ulrich Spengler‡,3,4

1Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany
3Department of Internal Medicine I, University of Bonn, Bonn, Germany
4Center for Integrated Oncology Cologne/Bonn, Bonn, Germany
5Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany
7Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany

#These authors contributed equally to this work.

‡These authors shared equal senior authorship.

*Correspondence to: Dominik Bettinger, Department of Medicine II, Medical Center University of Freiburg, Hugstetter Str. 55, Freiburg 79106, Germany. Tel: +49-761-270-32440, Fax: +49-761-270-32440, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(2):237-240 DOI: 10.14218/JCTH.2017.00063
Received: October 4, 2017 Accepted: December 14, 2017 Published online: January 18, 2018

Abstract

Hepatitis E virus infection is usually a self-limited disease. However, during the last years there has been growing evidence for prolonged and chronic infection occurring in patients with immunosuppression. Also patients with malignant and rheumatic diseases have been identified to be at risk for chronic hepatitis E. However, their course and prognosis are not well characterized and there have been no reports of hepatitis E virus infection in patients with gynecological cancer. Here, we report three Caucasian females with breast and ovarian cancers presenting with elevation of aminotransferase levels during anticancer treatment. Although only few or no clinical hints suggested hepatitis E virus infection, the diagnosis of hepatitis E virus infection was confirmed by seroconversion, which might occur with some delay, and/or by polymerase chain reaction. While two patients had a self-limited course, the third patient with a high-risk oncological constellation required ribavirin in order to resume chemotherapy. These cases highlight the need for hepatitis E virus testing in patients with gynecological cancer and elevated aminotransferase levels. Further, these cases show that in selected high-risk patients, ribavirin treatment may be necessary based on the decision of a multidisciplinary team.

Keywords

Hepatitis E, Gynecological cancer, Liver function test, Chemotherapy, Immunosuppression

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 135-140  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners

Category: Vol 6 Issue 2
Hits: 42

REVIEW ARTICLE

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners

Francesca Patella1, Filippo Pesapane*,1, Enrico Maria Fumarola1, Ilaria Emili1, Riccardo Spairani1, Salvatore Alessio Angileri2, Silvia Tresoldi2, Giuseppe Franceschelli2 and Gianpaolo Carrafiello2

1Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Milan, Italy
2Department of Health Sciences, Diagnostic and Interventional Radiology, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy

*Correspondence to: Filippo Pesapane, Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Via Festa del Perdono 7, Milan 20122, Italy. Tel: +39-13012751123; Fax: +39-2-50323393; E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(2):222-236 DOI: 10.14218/JCTH.2017.00062
Received: September 30, 2017 Accepted: December 5, 2017 Published online: February 22, 2018

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second leading cause of cancer-related deceases worldwide. Early diagnosis is essential for correct management and improvement of prognosis. Proposed for the first time in 2011 and updated for the last time in 2017, the Liver Imaging-Reporting and Data System (LI-RADS) is a comprehensive system for standardized interpretation and reporting of computed tomography (CT) and magnetic resonance imaging (MRI) liver examinations, endorsed by the American College of Radiology to achieve congruence with HCC diagnostic criteria in at-risk populations. Understanding its algorithm is fundamental to correctly apply LI-RADS in clinical practice. In this pictorial review, we provide a guide for beginners, explaining LI-RADS indications, describing major and ancillary features and eventually elucidating the diagnostic algorithm with the use of some clinical examples.

Keywords

LI-RADS, Hepatocellular carcinoma (HCC), Cirrhotic livers, Radiology

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 222-236  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home